 This is a multi-center, open-label trial of orally administered CA-4948 monotherapy in adult patients with Relapsed or Refractory NHL. The trial will be conducted in 2 parts: an initial Dose Escalation Phase Part A of CA-4948 in patients with Relapsed or Refractory Non-Hodgkin Lymphoma, RR NHL and a Dose Expansion Phase Part B of CA-4948 in patients with RR NHL with and without myeloid differentiation primary response 88 MYD88 mutations. During Part B, patients will be enrolled regardless of MYD88 mutation status. 